These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32685241)

  • 21. Three-year follow-up of sacral nerve stimulation for patients with diarrhoea-predominant and mixed irritable bowel syndrome.
    Fassov J; Lundby L; Laurberg S; Buntzen S; Krogh K
    Colorectal Dis; 2017 Feb; 19(2):188-193. PubMed ID: 27328645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome.
    Saulnier DM; Riehle K; Mistretta TA; Diaz MA; Mandal D; Raza S; Weidler EM; Qin X; Coarfa C; Milosavljevic A; Petrosino JF; Highlander S; Gibbs R; Lynch SV; Shulman RJ; Versalovic J
    Gastroenterology; 2011 Nov; 141(5):1782-91. PubMed ID: 21741921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies.
    Wang L; Alammar N; Singh R; Nanavati J; Song Y; Chaudhary R; Mullin GE
    J Acad Nutr Diet; 2020 Apr; 120(4):565-586. PubMed ID: 31473156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review.
    Dale HF; Rasmussen SH; Asiller ÖÖ; Lied GA
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31480656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update).
    McKenzie YA; Thompson J; Gulia P; Lomer MC;
    J Hum Nutr Diet; 2016 Oct; 29(5):576-92. PubMed ID: 27265510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
    Cox SR; Lindsay JO; Fromentin S; Stagg AJ; McCarthy NE; Galleron N; Ibraim SB; Roume H; Levenez F; Pons N; Maziers N; Lomer MC; Ehrlich SD; Irving PM; Whelan K
    Gastroenterology; 2020 Jan; 158(1):176-188.e7. PubMed ID: 31586453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot feasibility study of an unguided, internet-delivered cognitive behavioral therapy program for irritable bowel syndrome.
    Owusu JT; Sibelli A; Moss-Morris R; van Tilburg MAL; Levy RL; Oser M
    Neurogastroenterol Motil; 2021 Nov; 33(11):e14108. PubMed ID: 33745228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for faecal microbiota transplantation in irritable bowel syndrome: the MISCEAT study - a randomised, double-blind cross-over study using mixed microbiota from healthy donors.
    Hurych J; Vejmelka J; Hlinakova L; Kramna L; Larionov V; Kulich M; Cinek O; Kohout P
    BMJ Open; 2022 Jun; 12(6):e056594. PubMed ID: 35760542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.
    Chong PP; Chin VK; Looi CY; Wong WF; Madhavan P; Yong VC
    Front Microbiol; 2019; 10():1136. PubMed ID: 31244784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low fermentable oligo-di-mono-saccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled trial.
    Zahedi MJ; Behrouz V; Azimi M
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1192-1199. PubMed ID: 29159993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How can probiotic improve irritable bowel syndrome symptoms?
    Benjak Horvat I; Gobin I; Kresović A; Hauser G
    World J Gastrointest Surg; 2021 Sep; 13(9):923-940. PubMed ID: 34621470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, controlled, crossover study of sacral nerve stimulation for irritable bowel syndrome.
    Fassov JL; Lundby L; Laurberg S; Buntzen S; Krogh K
    Ann Surg; 2014 Jul; 260(1):31-6. PubMed ID: 24509204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial.
    Hunt M; Miguez S; Dukas B; Onwude O; White S
    JMIR Mhealth Uhealth; 2021 May; 9(5):e26152. PubMed ID: 33872182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.
    Lackner JM; Ma CX; Keefer L; Brenner DM; Gudleski GD; Satchidanand N; Firth R; Sitrin MD; Katz L; Krasner SS; Ballou SK; Naliboff BD; Mayer EA
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1147-57. PubMed ID: 23524278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome.
    Vicari E; Salemi M; Sidoti G; Malaguarnera M; Castiglione R
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29099760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
    Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J
    Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.